Granted Patent
B2
US 12,655,447 · App. 17/279,501 · Granted Jun 16, 2026
Compositions and methods for the treatment of skin diseases
Inventors:
Suma Krishnan (San Francisco, CA); Pooja Agarwal (Mars, PA); Trevor Parry (San Diego, CA)
Assignee:
Krystal Biotech, Inc.
C12N15/86A61K9/0019A61K47/02A61K47/26A61K47/38A61P17/02C07K14/78C12N7/00A61K38/00C12N2710/16021C12N2710/16043C12N2710/16062C12N2710/16071
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide and/or a filaggrin polypeptide; viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Claims (20)
1 . A pharmaceutical composition useful for delivery of one or more polynucleotides encoding a human filaggrin polypeptide to the skin of a subject having a skin disease, the pharmaceutical composition comprising:
a) a herpes simplex virus comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the human filaggrin polypeptide; and
b) a pharmaceutically acceptable excipient,
wherein the skin disease is selected from the group consisting of atopic dermatitis, ichthyosis vulgaris, and a peeling skin syndrome,
wherein the one or more polynucleotides encoding the human filaggrin polypeptide does not comprise a ribonucleic acid (RNA), and
wherein the recombinant herpes simplex virus genome does not comprise a polynucleotide encoding a collagen polypeptide, a fibronectin polypeptide, an elastin polypeptide, a lumican polypeptide, a vitronectin polypeptide, a vitronectin receptor polypeptide, a neuromodulator polypeptide, a fibrillin polypeptide, a laminin polypeptide, or a transglutaminase polypeptide.
2 . The pharmaceutical composition of claim 1 , wherein the herpes simplex virus is replication defective.
3 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is suitable for topical, transdermal, subcutaneous, intradermal, oral, sublingual, buccal, rectal, vaginal, inhaled, intravenous, intraarterial, intramuscular, intracardiac, intraosseous, intraperitoneal, transmucosal, intravitreal, subretinal, intraarticular, peri-articular, local, or epicutaneous administration.
4 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is suitable for topical administration.
5 . The pharmaceutical composition of claim 1 , wherein the filaggrin polypeptide comprises a sequence having at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 39-50.
6 . A method of providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of a skin disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising;
a) a herpes simplex virus comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding a human filaggrin polypeptide; and
b) a pharmaceutically acceptable excipient,
wherein the skin disease is selected from the group consisting of atopic dermatitis, ichthyosis vulgaris, and a peeling skin syndrome,
wherein the one or more polynucleotides encoding the human filaggrin polypeptide does not comprise a ribonucleic acid (RNA), and
wherein the recombinant herpes simplex virus genome does not comprise a polynucleotide encoding a collagen polypeptide, a fibronectin polypeptide, an elastin polypeptide, a lumican polypeptide, a vitronectin polypeptide, a vitronectin receptor polypeptide, a neuromodulator polypeptide, a fibrillin polypeptide, a laminin polypeptide, or a transglutaminase polypeptide.
7 . The method of claim 6 , wherein the subject is a human.
8 . The method of claim 6 , wherein the pharmaceutical composition is administered topically, transdermally, subcutaneously, epicutaneously, intradermally, orally, sublingually, buccally, rectally, vaginally, intravenously, intraarterially, intramuscularly, intraosseously, intracardially, intraperitoneally, transmucosally, intravitreally, subretinally, intraarticularly, periarticularly, locally, or via inhalation to the subject.
9 . The pharmaceutical composition of claim 1 , wherein the recombinant herpes simplex virus genome is a recombinant herpes simplex virus type 1 (HSV-1) genome or a recombinant herpes simplex virus type 2 (HSV-2) genome.
10 . The method of claim 6 , wherein the recombinant herpes simplex virus genome is a recombinant herpes simplex virus type 1 (HSV-1) genome or a recombinant herpes simplex virus type 2 (HSV-2) genome.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 24, 2021
From: KRISHNAN, SUMA; AGARWAL, POOJA; PARRY, TREVOR
To: KRYSTAL BIOTECH, INC.
Reel/Frame 055706/0423 →
Continuity (3)
Provisional Application
62744531
· Oct 11, 2018
Provisional Application
62737009
· Sep 26, 2018
References Cited (308)
US 5658724A
· Deluca et al.
· 1997
[cited by applicant]
US 5672344A
· Kelley et al.
· 1997
[cited by applicant]
US 5753234A
· Lee et al.
· 1998
[cited by applicant]
US 5998174A
· Glorioso et al.
· 1999
[cited by applicant]
US 6106826A
· Brandt et al.
· 2000
[cited by applicant]
US 6719982B1
· Coffin et al.
· 2004
[cited by applicant]
US 6846670B2
· Schwartz et al.
· 2005
[cited by applicant]
US 6887490B1
· Jahoda et al.
· 2005
[cited by applicant]
US 7081483B2
· Cahiko
· 2006
[cited by applicant]
US 7531167B2
· Glorioso et al.
· 2009
[cited by applicant]
US 9314505B2
· Wise et al.
· 2016
[cited by applicant]
US 9770489B2
· Angel et al.
· 2017
[cited by applicant]
US 9877990B2
· Krishnan et al.
· 2018
[cited by applicant]
US 20020037575A1
· Speck
· 2002
[cited by applicant]
US 20030082142A1
· Coffin et al.
· 2003
[cited by applicant]
US 20030190637A1
· Hovnanian et al.
· 2003
[cited by applicant]
US 20040005663A1
· Bell et al.
· 2004
[cited by applicant]
US 20040018592A1
· Bell et al.
· 2004
[cited by applicant]
US 20040253606A1
· Aziz et al.
· 2004
[cited by applicant]
US 20050255085A1
· Fong et al.
· 2005
[cited by applicant]
US 20070066552A1
· Clarke et al.
· 2007
[cited by applicant]
US 20070092575A1
· Balaban et al.
· 2007
[cited by applicant]
US 20070148074A1
· Sadoqi et al.
· 2007
[cited by applicant]
US 20080299182A1
· Zhang
· 2008
[cited by applicant]
US 20100081707A1
· Ali et al.
· 2010
[cited by applicant]
US 20110245592A1
· Schoolcraft et al.
· 2011
[cited by applicant]
US 20150265688A1
· Cigarini et al.
· 2015
[cited by applicant]
US 20150352191A1
· South et al.
· 2015
[cited by applicant]
US 20180353614A1
· Peters
· 2018
[cited by applicant]
US 20220273737A1
· Krishnan et al.
· 2022
[cited by applicant]
CN 102212559
· 2014
[cited by applicant]
JP 2008174459
· 2008
[cited by applicant]
JP 2015221759
· 2015
[cited by applicant]
JP 2017518370A
· 2017
[cited by applicant]
WO WO1999064094
· 1999
[cited by applicant]
WO WO2000040734
· 2000
[cited by applicant]
WO 2005103237A1
· 2005
[cited by applicant]
WO WO2006052285
· 2006
[cited by applicant]
WO WO2007136428
· 2007
[cited by applicant]
WO 2010021738A2
· 2010
[cited by applicant]
WO 2011063320A2
· 2011
[cited by applicant]
WO WO2012001170
· 2012
[cited by applicant]
WO WO2013119880
· 2013
[cited by applicant]
WO WO2013121202
· 2013
[cited by applicant]
WO WO2014043189
· 2014
[cited by applicant]
WO WO2015009952
· 2015
[cited by applicant]
WO WO2015117021
· 2015
[cited by applicant]
WO 2015184134A1
· 2015
[cited by applicant]
WO WO2015181211
· 2015
[cited by applicant]
WO WO2016128374
· 2016
[cited by applicant]
WO WO2016128783
· 2016
[cited by applicant]
WO WO2016141315
· 2016
[cited by applicant]
WO WO2016191684
· 2016
[cited by applicant]
WO WO2017165806
· 2017
[cited by applicant]
WO WO2017165813
· 2017
[cited by applicant]
WO 2017180587A2
· 2017
[cited by applicant]
WO WO2017176336
· 2017
[cited by applicant]
WO 2017191274A2
· 2017
[cited by applicant]
WO WO2017191315
· 2017
[cited by applicant]
WO WO2018154412A1
· 2018
[cited by examiner]
WO WO2019210219
· 2019
[cited by applicant]
WO WO2020069018
· 2020
[cited by applicant]
Kallunki P, et. al. Laminin, gamma 2 isoform b precursor [
[cited by examiner]
Sybert VP, et. al. Filaggrin [
[cited by examiner]
Xu X, Ma Q, Lin M, et al. A loss of function mutation in the filaggrin gene associated with ichthyosis vulgaris and rheumatoid arthritis. European Journal of Inflammation. 2021;19. (Year: 2021).
[cited by examiner]
“Rheumatoid arthritis.” Mayo Foundation for Medical Education and Research (MFMER). 2024; Accessed Jan. 10, 2024. https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/symptoms-causes/syc-20353648?p=1. (Ye…
[cited by examiner]
Parente MG, et. al. Collagen alpha-1(VII) chain precursor [
[cited by examiner]
Agrawal et al., “Skin Barrier Defects in Atopic Dermatitis,” Curr Allergy Asthma Rep (2014) 14(5): 433 pp. 1-11.
[cited by applicant]
Aldawsari et al., “Progress in Topical siRNA Delivery Approaches for Skin Disorders,” Curr Pharm Des. (2015) 21(31): 4594-4605.
[cited by applicant]
Andtbacka et. al., “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma,” J Clin Oncol. (2015) 33(25): 2780-2788.
[cited by applicant]
Anonymous, “Public summary of opinion on orphan designation Genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII for treatment of epidermolysis bullosa”, May 15, 2018 (May 15, 2018…
[cited by applicant]
Anonymous, “First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa.”, Aug. 6, 2018 (Aug. 6, 2018), p. 1-10, Retrieve…
[cited by applicant]
Anonymous, “Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa”, Apr. 26, 2018 (Apr. 26, 2018), p. 1-2, Retrieved from the Internet:…
[cited by applicant]
Antonov et al., “Methods for the Assessment of Barrier Function,” Curr Probl Dermatol. (2016) 49:61-70.
[cited by applicant]
Armstrong, M. “Krystal gets more skin in the epidermolysis bullosa game.” Vantage. Mar. 5, 2019.
[cited by applicant]
Armstrong, M. “Krystal gets a flying start in epidermolysis bullosa gene therapy” Vantage. Oct. 17, 2018.
[cited by applicant]
Asgari et al., “In vitro fibrillogenesis of tropocollagen type III in collagen type I affects its relative fibrillar topology and mechanics,” Scientific Reports (2017) 7 Article ID:1392.
[cited by applicant]
Bastian et al., “Herpes simplex virus type 1 immediate-early protein ICP22 is required for VICE domain formation during productive viral infection.” J Viral. Mar. 2010;84(5):2384-94. doi: 10.1128/JVI.01686-09. Epub Dec.…
[cited by applicant]
Baumann et al., “Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study,” Dermatol Surg (2007) 33 Suppl 2:s128-135.
[cited by applicant]
Berkers et al., “Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis,” Cell Rep (2019) 26(7): 1701-1708.e3.
[cited by applicant]
Birket et al., “Development of an airway mucus defect in the cystic fibrosis rat,” JCI Insight (2018) 3(1): e97199.
[cited by applicant]
Bowen et al., Comparison of Herpes Simplex Virus 1 Strains Circulating in Finland Demonstrates the Uncoupling of Whole-Genome Relatedness and Phenotypic Outcomes of Viral Infection, J Virol. (2019) 93(8):e01824-18.
[cited by applicant]
Brehm et al., “Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0,” Virology (1999) 256(2): 258-69.
[cited by applicant]
Brown et al., “Subject global evaluation and subject satisfaction using injectable poly-L-lactic acid versus human collagen for the correction of nasolabial fold wrinkles,” Plast Reconstr Surg (2011) 127(4):1684-1692.
[cited by applicant]
Burton et al., “Gene delivery using herpes simplex virus vectors.” DNA Cell Biol. Dec. 2002;21(12):915-936.
[cited by applicant]
Chamorro et al., “Gene Editing for the Efficient Correction of a Recurrent COL7A1 Mutation in Recessive Dystrophic Epidermolysis Bullosa Keratinocytes”, Molecular Therapy—Nucleic Acids, vol. 5, 2016, pp. 1-13.
[cited by applicant]
Cheng et al., “The content and ratio of type I and III collagen in skin differ with age and injury,” African Journal of Biotechnology (2011) 10(13):2524-2529.
[cited by applicant]
Christiano AM. Collagen, type VII, alpha 1 (epidermolysis bullosa, dystrophic, dominant and recessive) [
[cited by applicant]
Clancy et al., “Personalized Medicine in Cystic Fibrosis: Dawning of a New Era,” Am J Respir Crit Care Med (2012) 186(7): 593-597.
[cited by applicant]
Clancy et al., “CFTR Modulator Theratyping: Current Status, Gaps and Future Directions,” J Cyst Fibros (2019) 18(1): 22-34.
[cited by applicant]
Clinicaltrials.gov. NCT03536143: Topical Bercolagene Telserpavec (KB103) Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa (GEM-1). May 24, 2018.
[cited by applicant]
Clinicaltrials.gov. NCT04047732: Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosonnal Recessive Congenital Ichthyosis (ARCI). Aug. 7, 2019.
[cited by applicant]
Clinicaltrials.gov. NCT04214002: The Natural History of Wounds in Patients with Dystrophic Epidermolysis Bullosa (DEB). Dec. 30, 2019.
[cited by applicant]
Cole et al., “Extracellular matrix regulation of fibroblast function: redefining our perspective on skin aging,” Journal of Cell Communication and Signaliing (2018) 12:35-43.
[cited by applicant]
Collawn et al., “CFTR and Lung Homeostasis,” Am J Physiol Lung Cell Mol Physiol (2014) 307(12): L917-923.
[cited by applicant]
Communication pursuant to Article 94(3) EPC for EP 16826873.8, dated Apr. 17, 2019, 7 pages.
[cited by applicant]
Cooney et al., “Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward,” Genes (Basel) (2018) 9(11): 538.
[cited by applicant]
Cutting, G. “Cystic Fibrosis Genetics: From Molecular Understanding to Clinical Application,” Nat Rev Genet (2015) 16(1): 45-56.
[cited by applicant]
De Silva et al., “Herpes Virus Amplicon Vectors,” Viruses. (2009) 1(3):594-629.
[cited by applicant]
Dekkers et al., “A Functional CFTR Assay Using Primary Cystic Fibrosis Intestinal Organoids,” Nat Med (2013) 19(7): 939-945.
[cited by applicant]
Deluca et al., “Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4”, Journal Of Virology, (1985) 56(2): 558-570.
[cited by applicant]
Derichs et al., “Hyperviscous Airway Periciliary and Mucous Liquid Layers in Cystic Fibrosis Measured by Confocal Fluorescence Photobleaching,” FASEB J (2011) 25(7): 2325-2332.
[cited by applicant]
Dingwell et al., “The Herpes Simplex Virus gE-gI Complex Facilitates Cell-to-Cell Spread and Binds to Components of Cell Junctions,” J Virol. (1998) 72(11): 8933-8942.
[cited by applicant]
Eming SA, Krieg T, Davidson JM. Gene therapy and wound healing. Clin Dermatol. Jan.-Feb. 2007;25(1):79-92.
[cited by applicant]
Eming et al., “Gene transfer in tissue repair: status, challenges and future directions,” Exp Opin Biol Ther (2004) 4(9):1373-1386.
[cited by applicant]
Estrada-Veras et al., “Palliative Care for Patients With Cystic Fibrosis #265,” J Palliat Med (2013) 16(4): 446-447.
[cited by applicant]
European Medicines Agency, “Assessment Report on Imlygic,” Published Oct. 22, 2015.
[cited by applicant]
Examination Report No. 1 received for Australian Patent Application No. 2016401692, , mailed on Jul. 12, 2019, 4 pages.
[cited by applicant]
Fath et al., “Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression,” PLoS One. (2011) 6(3): e17596.
[cited by applicant]
FDA Briefing Document, “Cellular, Tissue, and Gene Therpies Advisory Committee and Oncologic Drugs Advisory Committee Meeting,” Dated Apr. 29, 2015.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 15/393,151, mailed on Aug. 31, 2017, 13 pages.
[cited by applicant]
Fink et al., “Gene therapy for pain: Results of a Phase I clinical trial,” Ann Neurol (2011) 70(2):207-212.
[cited by applicant]
Fink, “Gene transfer to the peripheral nervous system: Treatments for polyneuropathy and for pain,” (2011).
[cited by applicant]
Fisher et al., “Pathophysiology of Premature Skin Aging Induced by Ultraviolet Light,” N Engl J Med (1997) 337:1419-1429.
[cited by applicant]
Ganceviciene et al., “Skin anti-aging strategies,” Dermato-endocrinology (2012) 4:308-319.
[cited by applicant]
Geller et al., “An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology,” Proc Natl Acad Sci U S A. (1990) 87(22): 8…
[cited by applicant]
Georgiadis et al., “Lentiviral Engineered Fibroblasts Expressing Codon-Optimized COL7A1 Restore Anchoring Fibrils in RDEB”, Journal of Investigative Dermatology, (2016) 136: 284-292.
[cited by applicant]
Gill et al., “Delivery of Genes Into the CF Airway,” Thorax (2014) 69(10): 962-964.
[cited by applicant]
Glorioso JC. “Herpes simplex viral vectors: late bloomers with big potential.” Hum Gene Ther. (2014) 25(2): 83-91.
[cited by applicant]
Goins et al. “Engineering HSV-1 Vectors for Gene Therapy,” Methods Mol Biol (2014) 1144: 63-79.
[cited by applicant]
Goldsmith et al., “Infected cell protein (ICP)47 enhances herpes simplex virus neurovirulence by blocking the CD8+ T cell response,” J Exp Med. (1998) 187(3): 341-8.
[cited by applicant]
Gorell et al., “Gene therapy for skin diseases,” Cold Spring Harb Perspect Med (2014) 4:a015149.
[cited by applicant]
Gorouchi et al., “Role of topical peptides in preventing or treating aged skin,” International Journal of Cosmetic Science (2009) 31:327-345.
[cited by applicant]
Goto et al., “Fibroblasts Show More Potential as Target Cells than Keratinocytes in COL7A1 Gene Therapy of Dystrophic Epidermolysis Bullosa”, Journal of Investigative Dermatology, (2006) 126: 766-772.
[cited by applicant]
Grant, Kyle, “Production and Purification of Highly Replication Defective Hsv-1 Based Gene Therapy Vectors”, Doctoral Dissertation, University of Pittsburgh, 2008, 137 pages.
[cited by applicant]
Gurevich et. al. 759 “Successful in vivo COL7A1 gene delivery and correction of recessive dystrophic epidermolysis bullosa (RDEB) skin using an off the shelf HSV-1 vector (KB103).” J Invest Derm. vol. 138, Iss. 5 Supp. …
[cited by applicant]
Harrington et al., “Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIB/C and IVMla melanoma: subanalysis of the Phase III OPTiM trial,” Onc…
[cited by applicant]
Harrow et al., “HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival,” Gene Therapy (2004) 11:1648-1658.
[cited by applicant]
Heikkinen et al., “Diremerization of human lysyl hydroxylase 3 (LH3) is mediated by the amino acids 541 547,” Matrix Biology (2010) 30(1):27-33.
[cited by applicant]
Hennig et al., “HEK293-based production platform for y-retroviral (self-inactivating) vectors: application for safe and efficient transfer of COL7A1 cDNA”. Hum Gene Ther Clin Dev. Dec. 2014;25(4):218-28.
[cited by applicant]
Humbert et al., “In the shadow of the wrinkle: experimental models,” Journal of Cosmetic Dermatology (2011) 11:79-83.
[cited by applicant]
Hyde et al., “Repeat Administration of DNA/liposomes to the Nasal Epithelium of Patients With Cystic Fibrosis,” Gene Ther (2000) 7(13): 1156-1165.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/068974, mailed on Oct. 18, 2018, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability for PCT/US2019/029422, dated Oct. 27, 2020, 5 pages.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2019/29422, dated Jul. 10, 2019, 13 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2016/068974, mailed on May 18, 2017, 18 pages.
[cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US2016/068974, mailed on Mar. 27, 2017, 8 pages.
[cited by applicant]
Kerem et al., “Identification of the Cystic Fibrosis Gene: Genetic Analysis,” Science (1989) 245(4922): 1073-1080.
[cited by applicant]
Kim et al., “Microneedles for Drug and Vaccine Delivery”, Advanced Drug Delivery Reviews, vol. 64, 2012, pp. 1547-1568.
[cited by applicant]
Kim et al., “Barriers to Inhaled Gene Therapy of Obstructive Lung Diseases: A Review,” J Control Release (2016) 240: 465-488.
[cited by applicant]
Knowles et al., “A Controlled Study of Adenoviral-Vector-Mediated Gene Transfer in the Nasal Epithelium of Patients With Cystic Fibrosis,” N Engl J Med (1995) 333(13): 823-831.
[cited by applicant]
Kohlhapp et al., Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy, Clinical Cancer Research (2015) 22(5):1048-1054.
[cited by applicant]
Kopecki et al., “Commentary: New advances in the development of therapies for treating inherited skin fragility disorders,” Wound Practice and Research (2015) 23(4): 184, Dec. 5, 2015.
[cited by applicant]
Krisky et al., “Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons,” Gene Ther. (1998) 5(12):1593-603.
[cited by applicant]
Krisky et al., “Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications,” Gene Ther (1998) 5(110):1517-1530.
[cited by applicant]
Lachmann, R. “Herpes simplex virus-based vectors,” Int J Exp Pathol. (2004) 85(4): 177-190.
[cited by applicant]
Lemperle et al., “A classification of facial wrinkles,” Plastic and Reconstructive Surgery (2001) 1735-1750.
[cited by applicant]
Lewin et al., “Gene therapy for autosomal dominant disorders of keratin,” J Investig Dermatol Symp Proc. (2005) 10(1): 47-61.
[cited by applicant]
Liou et al., “Year-to-year Changes in Lung Function in Individuals With Cystic Fibrosis,” J Cyst Fibros (2010) 9(4): 250-256.
[cited by applicant]
Liu et al., “The Use of Type I and Type III Injectable Human Collagen for Dermal Fill: 10 Years of Clinical Experience in China,” Semin Plast Surg (2005) 19(3):241-250.
[cited by applicant]
Liu et al., “Type III collagen is crucial for collagen I fibrillogenesis and for normal cardiovascular development,” Proc Natl Acad Sci USA (1997) 94:1852-1856.
[cited by applicant]
Lommatzsch et al., “The Combination of Tezacaftor and Ivacaftor in the Treatment of Patients With Cystic Fibrosis: Clinical Evidence and Future Prospects in Cystic Fibrosis Therapy,” Ther Adv Respir Dis (2019) 13: 1-13.…
[cited by applicant]
Lu et al., “Topical Application of Viral Vectors for Epidermal Gene Transfer”, J Invest Dermatol. (1997) 108(5): 803-808.
[cited by applicant]
Ma et al., “Efficacy of Herpes Simplex Virus Vector Encoding V the Human Preproenkephalin Gene for Treatment of Facial Pain in Mice,” J aral Facial Pain Headachce (2016) 30(1):42-50.
[cited by applicant]
Manservigi et al., “HSV Recombinant Vectors for Gene Therapy,” Open Virol J. (2010) 4:123-56.
[cited by applicant]
Marconi et al., “HSV as a Vector in Vaccine Development and Gene Therapy.” In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. 30 pages.
[cited by applicant]
Marconi et al., “Replication-defective herpes simplex virus vectors for gene transfer in vivo,” Proc Natl Acad Sci USA (1996) 93:11319-11320.
[cited by applicant]
Markert et al., “Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial,” Gene Ther (2000) 7:867-874.
[cited by applicant]
Mavilio et al., “Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells,” Nat Med. (2006) 12(12): 1397-1402.
[cited by applicant]
Mayr et al., “Gene Therapy for the COL7A1 Gene”, Chapter 23, Intech, 2013, pp. 561-589.
[cited by applicant]
Melo et al., “Somatic correction of junctional epidermolysis bullosa by a highly recombinogenic AAV variant,” Mol Ther. (2014) 22(4):725-33.
[cited by applicant]
Miezeiewski et al., “Role of adherens junction proteins in differential herpes simplex virus type 2 infectivity in communication-competent and -deficient cell lines,” Intervirology. (2012) 55(6): 465-474.
[cited by applicant]
Miyagawa et al., “Herpes simplex viral-vector design for efficient transfuction of nonneuronal cells without cytotoxcity,” Proc Natl Acad Sci USA (2015) 112(13):E1632-E1641.
[cited by applicant]
Miyagawa et al., “Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes,” Mol Ther Methods Clin Dev. (2017) 6: 79-90.
[cited by applicant]
Mokrejs et al., “IRESite: the database of experimentally verified IRES structures (www.iresite.org),” Nucleic Acids Res. (2006) 34(Database issue):D125-30.
[cited by applicant]
Nakao et al., “Intratumoral injection of herpes simplex virus HF10 in recurrent breast cancer,” Ann Oncol (2004) 15(6):988-989.
[cited by applicant]
Ng et al., “Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa”, Cancer Research, vol. 72, No. 14, Jul. 15, 20…
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 15/393,151, mailed on Apr. 14, 2017, 13 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 15/851,488, mailed on May 14, 2018, 10 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/177,153, mailed on May 9, 2019, 13 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 15/393,151, mailed on Dec. 6, 2017, 11 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 15/851,488, mailed on Oct. 29, 2018, 11 pages.
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/177,153, mailed on Aug. 30, 2019, 10 pages.
[cited by applicant]
Nuutila et al., “Recombinant human collagen III gel for transplantation of autologous skin cells in porcine full-thickness wounds,” J Tissue Eng Regen Med (2015) 9:1386-1393.
[cited by applicant]
Ortiz-Urda et al., “Injection of Genetically Engineered Fibroblasts Corrects Regenerated Human Epidermolysis Bullosa Skin Tissue”, The Journal of Clinical Investigation, vol. 111, No. 2, Jan. 2003, pp. 251-255.
[cited by applicant]
Papanastassiou et al., “The potential for efficacy of the modified (ICP 34.5-) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study,” Gene Ther (2002) 9:…
[cited by applicant]
Periphagen, Krystal Biotech Inc., Answer and Counterclaim in
[cited by applicant]
Qin et al., “Rapamycin Protects Skin Fibroblasts from Ultraviolet B-Induced Photoaging by Suppressing the Production of Reactive Oxygen Species,” Cell Physiol Biochem (2018) 46:1849-1860.
[cited by applicant]
Quan et al., “Role of Age-Associated Alterations of the Dermal Extracellular Matrix Microenvironment in Human Skin Aging,” Gerontology (2015) 61(5):427-434.
[cited by applicant]
Rahn et al., “Invasion of Herpes Simplex Virus Type 1 into Murine Epidermis: An Ex Vivo Infection Study,” J Invest Dermatol. (2015) 135(12): 3009-3016.
[cited by applicant]
Rampling et al., “Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma,” Gene Ther (2000) 7:859-866.
[cited by applicant]
Rayess et al., “A Cross-sectional Analysis of Adverse Events and Litigation for Injectable Fillers,” JAMA Facial Plast Surg (2018) 20(3):207-214.
[cited by applicant]
Ricard-Blum, “The Collagen Family,” Cold Spring Harb Perspect Biol (2011) 3:a004978.
[cited by applicant]
Rittie et al., “Natural and Sun-Induced Aging of Human Skin,” Cold Spring Harb Perspect Med (2015) 5:a015370.
[cited by applicant]
Salam A. “Krystal's KB103 splits experts' thoughts on potential for HSV-1 risk in dystrophic epidermolysis bullosa patients, but final Phase I/II efficacy assured.” Nov. 7, 2018. Biopharm Insight.
[cited by applicant]
Salameh et al., “Early events in herpes simplex virus lifecycle with implications for an infection of lifetime,” Open Virol J. (2012) 6:1-6.
[cited by applicant]
Salmon-Ehr et al., “Implication of Interleukin-4 in Wound Healing”, Laboratory Investigation, vol. 80, No. 8, Aug. 2000, pp. 1337-1343.
[cited by applicant]
Samaniego et al., “Persistence and Expression of the Herpes Simplex Virus Genome in the Absence of Immediate-Early Proteins”, Journal of Virology, (1998) 72(4); 3307-3320.
[cited by applicant]
Samaniego et al., “The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27,” J Virol. (1997) 71(6): 4614-4625.
[cited by applicant]
Sankar et al., “A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhersion in eqing sarcoma,” Molecular and Cellular Biology (2013) 33(22):4448-4460.
[cited by applicant]
Shen et al., “Herpes simplex virus 1 (HSV-1) for cancer treatment,” Cancer Gene Therapy (2006) 13: 975-992.
[cited by applicant]
Silva et al., “Herpes Virus Amplicon Vectors”, Viruses, vol. 1, 2009, pp. 594-629.
[cited by applicant]
Siprashvili et al., “Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue,” Hum Gene Ther. Oct. 2010;21(10):1299-310.
[cited by applicant]
Stow et al., Isolation and characterization of a herpes simplex virus type 1 mutant containing a deletion within the gene encoding the immediate early polypeptide Vmw110. J Gen Viral. Dec. 1986;67 ( Pt 12):2571-85.
[cited by applicant]
Sufiawati et al., “HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread,” PLoS One. (2014) 9(2): e88803.
[cited by applicant]
Sufiawati et al., “HIV-induced matrix metalloproteinase-9 activation through mitogen-activated protein kinase signalling promotes HSV-1 cell-to-cell spread in oral epithelial cells,” J Gen Virol. (2018) 99(7): 937-947.
[cited by applicant]
Summary of safety and effectiveness data of CosmoDerm™ 1 Human-Based collagen. Approval date to applicant Mar. 11, 2003.
[cited by applicant]
Thangapazham et al., “Alteration of Skin Properties with Autologous Dermal Fibroblasts,” Int J Mol Sci (2014) 15:8407-8427.
[cited by applicant]
Theopold et al., “A novel replication-defective HSV-1 vector for regulatable gene delivery to wounds,” Journal of the American College of Surgeons (2004) 199(3):57-58.
[cited by applicant]
Uitto et al., “Progress toward Treatment and Cure of Epidermolysis Bullosa: Summary of the DEBRA International Research Symposium EB2015”, Journal of Investigative Dermatology, vol. 136, 2016, pp. 352-358.
[cited by applicant]
Volk et al., “Diminished Type III Collagen Promotes Myofibroblast Differentiation and Increases Scar Deposition in Cutaneous Wound Healing,” Cells Tissues Organs (2011) 194:25-37.
[cited by applicant]
Von Heijne, G., “Patterns of amino acids near signal-sequence cleavage sites,” Eur J Biochem. Jun. 1, 1983;133(1):17-21.
[cited by applicant]
Wang et al., “Comparative Effectiveness of Antinociceptive Gene Therapies in Animal Models of Diabetic Neuropathic Pain”, Gene Therapy, vol. 20, 2013, pp. 742-750.
[cited by applicant]
Wang et al., “Wound healing,” J Chin Med Assoc (2018) 81:94-101.
[cited by applicant]
Watanabe et al., “Properties of a Herpes Simplex Virus Multiple Immediate-early Gene-Deleted Recombinant as a Vaccine Vector”, Virology, vol. 357, 2007, pp. 186-198.
[cited by applicant]
Watson et al., “Autologous Fibroblasts for Treatment of Facial Rhytids and Dermal Depressions,” Arch Facial Plast Surg (1999) 1:165-170.
[cited by applicant]
Watt et al., “Lysyl Hydroxylase 3 Localizes to Epidermal Basement Membrane and Is Reduced in Patients with Recessive Dystrophic Epidermolysis Bullosa”, Plos One, (2015) 10(9): e0137639.
[cited by applicant]
Weiss et al., “The Role of Interleukin 10 in the Pathogenesis and Potential Treatment of Skin Diseases”, Journal of the American Academy of Dermatology, vol. 50, No. 5, May 2004, pp. 657-675.
[cited by applicant]
White et al., “Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery,” Cancer Gene Ther. May 2011;18(5):358-69. doi: 10.1…
[cited by applicant]
Wikipedia, “Collagen, type VII, alpha 1,” Edited on Apr. 17, 2020. Retrieved from https://en.wikipedia.org/wiki/Collagen,_type_VII,_alpha_1&oldid=951427836 on Jul. 22, 2020.
[cited by applicant]
Wikipedia, “Collagen,” p. 1-10. Retrieved Aug. 20, 2019.
[cited by applicant]
Wolfe et al., “Engineering Herpes Simplex Viral Vectors for Therapeutic Gene Transfer”, Chapter 6, Gene and Cell Therapy, 2004, pp. 103-129.
[cited by applicant]
Woodley et al., “Normal and Gene-Corrected Dystrophic Epidermolysis Bullosa Fibroblasts Alone Can Produce Type VII Collagen at the Basement Membrane Zone”, The Journal of Investigative Dermatology, vol. 121, No. 5, Nov.…
[cited by applicant]
Woodley, et al., “Intradermal Injection of Lentiviral Vectors Corrects Regenerated Human Dystrophic Epidermolysis Bullosa Skin Tissue in Vivo”, Molecular Therapy, vol. 10, No. 2, Aug. 2004, pp. 318-326.
[cited by applicant]
Wu et al., “Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate-early genes encoding ICP4, ICP27, and ICP22,” J Virol. (1996) 70(9): 6358-6369.
[cited by applicant]
Yano et al., “Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan,” Regenerative Therapy (2015) 1:45-56.
[cited by applicant]
Yoon et al., “Anti-wrinkle effect of bone morphogenetic protein receptor 1a-extracellular domain (BMPR1a-ECD),” BMB Rep (2013) 46(9):465-470.
[cited by applicant]
Zeng et al., “Preclinical Safety Studies on Autologous Cultured Human Skin Fibroblast Transplantation,” Cell Transplant (2014) 23:39-49.
[cited by applicant]
Zhao et al., “Preliminary Survival Studies on Autologous Cultured Skin Fibroblasts Transplantation by Injection,” Cell Transplant (2008) 17:775-783.
[cited by applicant]
Unpublished U.S. Appl. No. 18/342,284, filed Jun. 27, 2023, by Krishnan et al. titled “Compositions and Methods for the Treatment of Wounds, Disorders, and Diseases of the Skin” (Copy not submitted herewith pursuant to …
[cited by applicant]
Acland et al., “Gene therapy restores vision in a canine model of childhood blindness,” Nat Genet. (2001) 28(1):92-5.
[cited by applicant]
Ali et al., “Gene therapy for inherited retinal degeneration,” Br J Ophthalmol. (1997) 81(9):795-801.
[cited by applicant]
Boehmer et al., “Herpes Virus Replication,” IUBMB Life (2003) 55(1):13-22.
[cited by applicant]
Boettiger, D., “Quantitative measurements of integrin-mediated adhesion to extracellular matrix,” Methods Enzymol. (2007) 426:1-25. Abstract only.
[cited by applicant]
Choate et al., “Transglutaminase 1 delivery to lamellar ichthyosis keratinocytes,” Human Gene Therapy (1996) 7:2247-2253.
[cited by applicant]
Di et al., “Phase I study protocol for ex vivo lentiviral gene therapy for the inherited skin disease, Netherton syndrome,” Hum Gene Ther Clin Dev. (2013) 24(4):182-190.
[cited by applicant]
Farasat et al., “Novel transglutaminase-1 mutations and genotype-phenotype investigations of 104 patients with autosomal recessive congenital ichthyosis in the USA,” J Med Genet (2009) 46(2):103-111.
[cited by applicant]
Fraefel et al., “In vivo gene transfer to the rat retina using herpes simplex virus type 1 (HSV-1)-based amplicon vectors,” Gene Ther. (2005) 12(16):1283-8.
[cited by applicant]
Goins et al. “Generation of replication-competent and -defective HSV vectors,” Cold Spring Harb Protoc. May 1, 2011;2011(5): 512-519; pdb.prot5615.
[cited by applicant]
Hegde et al., “The surprising complexity of signal sequences,” Trends Biochem Sci. (2006) 31(10): 563-571.
[cited by applicant]
Hill et al., “Herpes simplex virus turns off the TAP to evade host immunity,” Nature. (1995) 375(6530): 411-415.
[cited by applicant]
Krystal Biotech, Inc. “Krystal Biotech Announces Settlement with PeriphaGen, Inc.” Mar. 15, 2022, https://ir.krystalbio.com/node/8481/pdf. (Year: 2022).
[cited by applicant]
Liu et al., “Herpes simplex virus mediated gene transfer to primate ocular tissues,” Exp Eye Res. (1999) 69(4):385-95.
[cited by applicant]
Martoglio et al., “Signal sequences: more than just greasy peptides,” Trends Cell Biol. (1998) 8(10): 410-415.
[cited by applicant]
Mcgowan et al., “Keratin 17 n ull mice exhibit age- and strain-dependent alopecia,” Genes & Dev (2002) 16:1412-1422.
[cited by applicant]
Messmer et al., “Ocular manifestations of keratitis-ichthyosis-deafness (KID) syndrome,” Ophthalmology. (2005) 112(2):e1-6.
[cited by applicant]
Peek et al., “Herpes simplex virus infection of the human eye induces a compartmentalized virus-specific B cell response,” J Infect Dis. (2002) 186(11):1539-46.
[cited by applicant]
Pepose et al., “Herpes simplex viral vectors for therapeutic gene delivery to ocular tissues. Recent breakthroughs in the molecular genetics of ocular diseases,” Invest Ophthalmol Vis Sci. (1994) 35(6):2662-6.
[cited by applicant]
Robbins et al., “In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa,” Proc Natl Acad Sci USA (2001) 98(9):5193-5198.
[cited by applicant]
Sabater et al., “Topical beremagene geperpavec (B-VEC) for the treatment of recurrent cicatrizing conjunctivitis in a patient with dystrophic epidermolysis bullosa,” ARVO Annual Meeting, New Orleans, LA, USA, Apr. 23-27…
[cited by applicant]
Shtessel et al., “Reliability of allergy skin testing,” Ann Allergy Asthma Immunol. (2018) 120(1): 80-83. Abstract only.
[cited by applicant]
Siegle et al., “Intradermal Implantation of Bovine Collagen: Humoral Immune Responses Associated with Clinical Reactions,” Arch Dermatol (1984) 120:183-187.
[cited by applicant]
Smith et al., “A Randomized, Bilateral, Prospective Comparison of Calcium Hydroxylapatite Microspheres versus Human-Based Collagen for the Correction of Nasolabial Folds,” Dermatol Surg (2007) 33:S112-S121.
[cited by applicant]
Spencer et al., “HSV-1 vector-delivered FGF2 to the retina is neuroprotective but does not preserve functional responses,” Mol Ther. (2001) 3(5 Pt 1):746-56.
[cited by applicant]
Vauthier et al., “Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications,” Adv Drug Del Rev. (2003) 55: 519-48.
[cited by applicant]
Wang et al., “Updates on Gene Therapy for Diabetic Retinopathy,” Curr Diab Rep. (2020) 20(7):22.
[cited by applicant]
Yutskovskaya et al., “A Randomized, Split-Face, Histomorphological Study Comparing a Volumetric Calcium Hydroxylapatite and a Hyaluornic Acid-Based Dermal Filler,” J Drugs Dermatol (2014) 13(9):47-52.
[cited by applicant]
Goins, et al., “Herpes Simplex Virus Type 1 Vector-Mediated Expression of Nerve Growth Factor Protects Dorsal Root Ganglion Neurons from Peroxide Toxicity,” Journal of Virology, Jan. 1999, pp. 519-532, vol. 73, No. 1.
[cited by applicant]
Office Action for U.S. Appl. No. 18/342,284 dated Aug. 15, 2024.
[cited by applicant]
Ivanov et al., “A Tobamovirus Genome That Contains an Internal Ribosome Entry Site Functional in Vitro.” Virology, vol. 232, 1997, pp. 32-43.
[cited by applicant]
Sadikoglou et al., “Comparative analysis of internal ribosomal entry sites as molecular tools for bicistronic expression.” Journal of Biotechnology, vol. 181, 2014, pp. 31-34.
[cited by applicant]
Wang et al., “Neurological Complications of herpes zoster,” Zhejiang Medical Journal, Issue 6, pp. 26-28, 1985.
[cited by applicant]
Office Action for related Application No. CN 201980028654.6 dated Dec. 22, 2023.
[cited by applicant]
Office Action for related Application No. AE P6001497/2020 dated Dec. 4, 2023.
[cited by applicant]
Saeki et al., “Improved Helper Virus-Free Packaging System for HSV Amplicon Vectors Using an ICP27-Deleted, Oversized HSV-1 DNA in a Bacterial Artificial Chromosome.” Molecular Therapy. 2001. vol. 3, No. 4, pp. 591-601.
[cited by applicant]
Titeux et al., “Gene therapeutics strategies for blistering skin diseases.” Drug Discovery Today: Therapeutic Strategies. 2006. vol. 3, No. 1, pp. 87-92.
[cited by applicant]
Office Action from related Application KR 10-2018-7030112, dated Jan. 24, 2024.
[cited by applicant]
Office Action or Application No. NC 2023/0017711 dated Jan. 9, 2025.
[cited by applicant]
Office Action in Related Application No. CO NC20230017712 dated Nov. 19, 2024.
[cited by applicant]
Office Action in Application No. CN 201980028654.6 dated Aug. 30, 2024.
[cited by applicant]
Office Action in Related Application No. JP2024-027283, dated Feb. 20, 2025.
[cited by applicant]
Ain et al., “Gene Delivery to the Skin—How Far Have We Come?”, Trends in Biotechnology, 2020, pp. 474-487, 39 (5).
[cited by applicant]
Di et al., “Ex-vivo gene therapy restores LEKT1 activity and corrects the architecture of Netherton syndrome-derived skin grafts” Mol. Ther. 2011, pp. 408-416, 19(2).
[cited by applicant]
Ghazizadeh et al., “In vivo transduction of mouse epidermis with recombinant retroviral vectors: implications for cutaneous gene therapy” Gene Ther., 1999, pp. 1267-1275, vol. 6, No. 7.
[cited by applicant]
Perkins, “Targeting apoptosis in neurological diseasae using the herpes simplex virus”, Journal of Cellular and Molecular Medicine, 2002, pp. 341-356, 6(3).
[cited by applicant]
Roedl et al., “rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients” J. Dermatol. Sci., 2011, pp. 194-198, vol. 61, No. 3.
[cited by applicant]
Whitley et al., “Pathogenesis and disease,” In: Arvin A, Campadelli-Fiume G, Mocarski E, et al., eds. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis, 2007, Cambridge: Cambridge Univ. Press; 2007. Chapter 3…
[cited by applicant]
Office Action in related CA application 3,112,633 dated dated Apr. 16, 2024.
[cited by applicant]
Office Action for CO Application No. NC2023/0017711 dated May 6, 2025.
[cited by applicant]